{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:28:13Z","timestamp":1786962493703,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03748-4","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:01:40Z","timestamp":1786960900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative Complications Associated with Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1673-7792","authenticated-orcid":false,"given":"Mohammed Nabil","family":"Quraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam A.","family":"AlAhmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"El-Hussuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"5","key":"3748_CR1","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","volume":"145","author":"AD Frolkis","year":"2013","unstructured":"Frolkis AD, Dykeman J, Negr\u00f3n ME, deBruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996\u20131006. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.041. (PubMed PMID: 23896172).","journal-title":"Gastroenterology"},{"issue":"6","key":"3748_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394. https:\/\/doi.org\/10.1053\/j.gastro.2011.01.055. (PubMed PMID: 21530745).","journal-title":"Gastroenterology"},{"issue":"8","key":"3748_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/ajg.2012.127","volume":"107","author":"LE Targownik","year":"2012","unstructured":"Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107(8):1228\u201335. https:\/\/doi.org\/10.1038\/ajg.2012.127. (PubMed PMID: 22613902).","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"3748_CR4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","volume":"19","author":"L Tsai","year":"2021","unstructured":"Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021;19(10):2031-2045.e11. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.039. (PubMed PMID: 33127595; PubMed Central PMCID: PMC8934200).","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"6","key":"3748_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","volume":"22","author":"S Vieujean","year":"2025","unstructured":"Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2025;22(6):371\u201394. https:\/\/doi.org\/10.1038\/s41575-024-01035-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"3748_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1007\/s11605-008-0646-0","volume":"12","author":"KA Appau","year":"2008","unstructured":"Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn\u2019s patients. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2008;12(10):1738\u201344. https:\/\/doi.org\/10.1007\/s11605-008-0646-0. (PubMed PMID: 18709420).","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"5","key":"3748_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","volume":"204","author":"CR Selvasekar","year":"2007","unstructured":"Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956\u201362 (discussion 962\u20133). (PubMed PMID: 17481518).","journal-title":"J Am Coll Surg"},{"issue":"3","key":"3748_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4240\/wjgs.v8.i3.274","volume":"8","author":"P Waterland","year":"2016","unstructured":"Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn\u2019s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg. 2016;8(3):274\u201383. https:\/\/doi.org\/10.4240\/wjgs.v8.i3.274. (PubMed PMID: 27022455; PubMed Central PMCID: PMC4807329).","journal-title":"World J Gastrointest Surg"},{"issue":"23","key":"3748_CR9","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.3390\/jcm11236884","volume":"11","author":"K Cira","year":"2022","unstructured":"Cira K, Weber MC, Wilhelm D, Friess H, Reischl S, Neumann PA. The effect of anti-tumor necrosis factor-alpha therapy within 12 weeks prior to surgery on postoperative complications in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Med. 2022;11(23):6884. https:\/\/doi.org\/10.3390\/jcm11236884. (PubMed PMID: 36498459; PubMed Central PMCID: PMC9738467).","journal-title":"J Clin Med"},{"issue":"S1","key":"3748_CR10","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/DCR.0000000000003222","volume":"67","author":"KE Lee","year":"2024","unstructured":"Lee KE, Sizemore JA, Kim G, Shen B, Sands BE. Impact of biologics and small-molecule agents on postoperative complications in IBD: a systematic review. Dis Colon Rectum. 2024;67(S1):S11\u201325. https:\/\/doi.org\/10.1097\/DCR.0000000000003222. (PubMed PMID: 38294838).","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"3748_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.gastro.2022.03.057","volume":"163","author":"BL Cohen","year":"2022","unstructured":"Cohen BL, Fleshner P, Kane SV, Herfarth HH, Palekar N, Farraye FA, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology. 2022;163(1):204\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.057. (PubMed PMID: 35413359).","journal-title":"Gastroenterology"},{"issue":"10","key":"3748_CR12","doi-asserted-by":"publisher","first-page":"CD013256","DOI":"10.1002\/14651858.CD013256.pub2","volume":"10","author":"CC Law","year":"2020","unstructured":"Law CC, Bell C, Koh D, Bao Y, Jairath V, Narula N. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev. 2020;10(10):CD013256. https:\/\/doi.org\/10.1002\/14651858.CD013256.pub2. (PubMed PMID: 33098570; PubMed Central PMCID: PMC8094278).","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"3748_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otz021","volume":"1","author":"A El-Hussuna","year":"2019","unstructured":"Open Source Research Collaborating Group, El-Hussuna A. Biological treatment and the potential risk of adverse postoperative outcome in patients with inflammatory bowel disease: an open-source expert panel review of the current literature and future perspectives. Crohns Colitis 360. 2019;1(3):otz021. https:\/\/doi.org\/10.1093\/crocol\/otz021.","journal-title":"Crohns Colitis 360"},{"issue":"10","key":"3748_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3390\/ph18101466","volume":"18","author":"AE Menni","year":"2025","unstructured":"Menni AE, Tzikos G, Petrakis G, Goulas P, Karathanasis PV, Apostolidis S. Comparative risk of complications following intestinal surgery after infliximab, vedolizumab, or ustekinumab treatment: systematic review & meta-analysis. Pharmaceuticals. 2025;18(10):1466. https:\/\/doi.org\/10.3390\/ph18101466. (PubMed PMID: 41155581; PubMed Central PMCID: PMC12567440).","journal-title":"Pharmaceuticals"},{"key":"3748_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71. (PubMed PMID: 33782057; PubMed Central PMCID: PMC8005924).","journal-title":"BMJ"},{"key":"3748_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. https:\/\/doi.org\/10.1002\/9781119536604."},{"issue":"2","key":"3748_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/ecco-jcc\/jjac129","volume":"17","author":"S Sebastian","year":"2023","unstructured":"Sebastian S, Segal JP, Hedin C, Pellino G, Kotze PG, Adamina M, et al. ECCO topical review: roadmap to optimal peri-operative care in IBD. J Crohns Colitis. 2023;17(2):153\u201369. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac129. (PubMed PMID: 36055337).","journal-title":"J Crohns Colitis"},{"key":"3748_CR18","unstructured":"R Core Team (2025) R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing"},{"issue":"2","key":"3748_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjz129","volume":"14","author":"M Novello","year":"2020","unstructured":"Novello M, Stocchi L, Steele SR, Holubar SD, Duraes LC, Kessler H, et al. Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs other biologics. J Crohns Colitis. 2020;14(2):185\u201391. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz129.","journal-title":"J Crohns Colitis"},{"key":"3748_CR20","doi-asserted-by":"publisher","first-page":"175628482093708","DOI":"10.1177\/1756284820937089","volume":"13","author":"J Zanelli","year":"2020","unstructured":"Zanelli J, Chandrapalan S, Patel A, Arasaradnam RP. The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis. Ther Adv Gastroenterol. 2020;13:1756284820937089. https:\/\/doi.org\/10.1177\/1756284820937089. (PubMed PMID: 33281933; PubMed Central PMCID: PMC7685679).","journal-title":"Ther Adv Gastroenterol"},{"issue":"12","key":"3748_CR21","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/ibd\/izac274","volume":"29","author":"D Bajz\u00e1t","year":"2023","unstructured":"Bajz\u00e1t D, K\u00e9ri AF, Imrei M, K\u00f3i T, P\u00e1rniczky A, Hegyi P, et al. Safety analysis of preoperative anti-TNF-\u03b1 therapy in pediatric IBD after intestinal resection: a systematic review and meta-analysis. Inflamm Bowel Dis. 2023;29(12):1971\u201380. https:\/\/doi.org\/10.1093\/ibd\/izac274. (PubMed PMID: 36789751).","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"3748_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s10620-021-06895-6","volume":"67","author":"J Hanzel","year":"2022","unstructured":"Hanzel J, Almradi A, Istl AC, Yang ML, Fleshner KA, Parker CE, et al. Increased risk of infections with anti-TNF agents in patients with Crohn\u2019s disease after elective surgery: meta-analysis. Dig Dis Sci. 2022;67(2):646\u201360. https:\/\/doi.org\/10.1007\/s10620-021-06895-6. (PubMed PMID: 33634430).","journal-title":"Dig Dis Sci"},{"issue":"6","key":"3748_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/apt.16222","volume":"53","author":"D Piovani","year":"2021","unstructured":"Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S. Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. Aliment Pharmacol Ther. 2021;53(6):712\u201321. https:\/\/doi.org\/10.1111\/apt.16222. (PubMed PMID: 33296517).","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3748_CR24","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.4240\/wjgs.v15.i11.2579","volume":"15","author":"RK Mowlah","year":"2023","unstructured":"Mowlah RK, Soldera J. Risk and management of post-operative infectious complications in inflammatory bowel disease: a systematic review. World J Gastrointest Surg. 2023;15(11):2579\u201395. https:\/\/doi.org\/10.4240\/wjgs.v15.i11.2579.","journal-title":"World J Gastrointest Surg"},{"issue":"8","key":"3748_CR25","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1007\/s00464-025-11919-7","volume":"39","author":"MM Mankarious","year":"2025","unstructured":"Mankarious MM, Dijoseph K, Greene AC, Schaefer EW, Clarke K, Deutsch MJ, et al. Exposure to advanced therapies and risk of surgery in Crohn\u2019s disease. Surg Endosc. 2025;39(8):5367\u201375. https:\/\/doi.org\/10.1007\/s00464-025-11919-7.","journal-title":"Surg Endosc"},{"issue":"8","key":"3748_CR26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/ibd\/izaf078","volume":"31","author":"M Gozdzik","year":"2025","unstructured":"Gozdzik M, Unninayar D, Siegal DM, Sarker AK, Kim E, Murthy S, et al. Risk factors for venous thromboembolism in inflammatory bowel disease: a systematic review and meta-analysis by phase of care. Inflamm Bowel Dis. 2025;31(8):2286\u201395. https:\/\/doi.org\/10.1093\/ibd\/izaf078.","journal-title":"Inflamm Bowel Dis"},{"key":"3748_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000004077","author":"SD Holubar","year":"2026","unstructured":"Holubar SD, Russell T, Neel N, Hull TL, Steinhagen RM, Bordeianou L, et al. Biologics before surgery are not associated with postoperative complications after surgery for inflammatory bowel disease: a national surgery quality improvement program inflammatory bowel disease collaborative causal inference analysis. Dis Colon Rectum. 2026. https:\/\/doi.org\/10.1097\/DCR.0000000000004077.","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"3748_CR28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/DCR.0b013e3182a0e702","volume":"56","author":"J Gu","year":"2013","unstructured":"Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-\u03b1 therapy. Dis Colon Rectum. 2013;56(11):1243\u201352. https:\/\/doi.org\/10.1097\/DCR.0b013e3182a0e702. (PubMed PMID: 24104999).","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"3748_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2015-311079. (PubMed PMID: 26893500).","journal-title":"Gut"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03748-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:01:45Z","timestamp":1786960905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":29,"alternative-id":["3748"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03748-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mohammed Nabil Quraishi has received speaker fees from Johnson & Johnson, Takeda, AbbVie, Hikma Pharmaceuticals and Abbott, and consultancy fees from Johnson & Johnson, AbbVie and Lilly. Badr Al-Bawardy has received speaker fees from AbbVie, Takeda, Bristol-Myers Squibb, Eli Lilly, Hikma and Janssen Pharmaceuticals, and consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer and Janssen. Maryam A. AlAhmad has nothing to disclose. Alaa El-Hussuna has nothing to disclose. Mohammed Nabil Quraishi is an Editorial Board member of Advances in Therapy. Mohammed Nabil Quraishi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required as this study is a systematic review and meta-analysis of previously published, aggregate data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}